SECUADO
Peakasenapine
NDATRANSDERMALSYSTEM
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
5/8 — Partial
SECUADO (asenapine) is 12. First approved in 2019.
Drug data last refreshed 52m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SECUADO is a transdermal system delivering asenapine, an atypical antipsychotic approved in 2019 for bipolar I disorder. The drug works through antagonism of multiple serotonin, dopamine, adrenergic, and histamine receptors, though its exact mechanism in bipolar disorder remains unclear. Its unique sublingual/transdermal route offers an alternative to oral formulations with improved bioavailability and patient adherence potential.
$5MPart D
Peak6.9 years to LOEProduct is at peak lifecycle stage with limited Part D penetration, suggesting a niche market focus requiring specialized commercial and medical affairs support for differentiation.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of asenapine in bipolar I disorder is unknown. 12.2 Pharmacodynamics Asenapine exhibits high affinity for serotonin 5-HT 1A , 5-HT 1B , 5-HT 2A , 5-HT 2B , 5-HT 2C , 5-HT 5A , 5-HT 6 , and 5-HT 7 receptors (Ki values of 2.5, 2.7, 0.07, 0.18, 0.03,…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.